0.40
-0.028(-6.54%)
Currency In USD
| Previous Close | 0.43 |
| Open | 0.42 |
| Day High | 0.41 |
| Day Low | 0.39 |
| 52-Week High | 2.88 |
| 52-Week Low | 0.39 |
| Volume | 1.56M |
| Average Volume | 913,822 |
| Market Cap | 118.14M |
| PE | -0.31 |
| EPS | -1.31 |
| Moving Average 50 Days | 0.53 |
| Moving Average 200 Days | 0.92 |
| Change | -0.03 |
If you invested $1000 in Lyell Immunopharma, Inc. (LYEL) since IPO date, it would be worth $23.68 as of May 09, 2025 at a share price of $0.4. Whereas If you bought $1000 worth of Lyell Immunopharma, Inc. (LYEL) shares 3 years ago, it would be worth $77.37 as of May 09, 2025 at a share price of $0.4.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
GlobeNewswire Inc.
Apr 15, 2025 1:00 PM GMT
RMAT designation was granted based on promising clinical data from the ongoing Phase 1/2 trial of LYL314 in patients with relapsed and/or refractory large B-cell lymphoma.RMAT designation recognizes the potential of LYL314 to address significant unme
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 18, 2025 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced today that membe
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 09, 2025 2:00 PM GMT
Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 and expect to initiate a pivotal trial in the 2nd line by early 2026Presenting additional data from the ongoing Phase 1-2 trial